Publications Repository

Publications Repository

View Item 
  •   Home
  • ICR Divisions
  • Other ICR Research
  • View Item
  • Home
  • ICR Divisions
  • Other ICR Research
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Strategies for Stalling Malignancy: Targeting Cancer’s Addiction to Hsp90

Thumbnail
Publication Date
2009-11
ICR Author
Prodromou, Chrisostomos
Author
Prodromou, C
Type
Journal Article
Metadata
Show full item record
Abstract
Hsp90 is involved in the maturation and activation of client proteins. Often these are key proteins involved in signal transduction and regulatory pathways that in a mutated and/or deregulated form sustain an oncogenic cellular state. Consequently, the malignancy is maintained with the aid of Hsp90 upon which the mutated proteins have become particularly dependent for their activity. The requirement for the Hsp90 chaperone machine to drive the malignancy makes Hsp90 a prime anticancer target, an ‘axle in a wheel’ that when disrupted has been shown to be effective in killing cancerous cells. This review aims to identify potential drug targets, based on the current structural knowledge of the Hsp90-chaperone machine, that could be targeted with the aim of disrupting its functioning and promoting an anti-cancer activity.
URL
https://repository.icr.ac.uk/handle/internal/2388
Collections
  • Other ICR Research
Version of record
10.2174/156802609789895656
Language
English
License start date
2009-11
Citation
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2009, 9 pp. 1352 - 1368
Publisher
BENTHAM SCIENCE PUBL LTD

Browse

All of ICR repositoryICR DivisionsIssue dateAuthorsTitlesSubjectsThis collectionIssue dateAuthorsTitlesSubjects

Statistics

Most popular itemsStatistics by countryMost popular authors
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.